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INTRODUCTION
Gastrointestinal stromal tumor (GIST) is a recently 
recognized pathology that originates from the interstitial cells 
of Cajal1 and is the most common mesenchymal neoplasm 
of the gastrointestinal tract. Although surgery is the only 
treatment available, it is only possible in approximately half 
of the cases2. This malignancy is characterized by a high risk 
of metastatic relapse, specifically in the liver and peritoneum. 
Imatinib mesylate, a tyrosine kinase inhibitor that inhibits 
c-kit signal transduction, is often used as a treatment for 
metastatic GIST. 
Neoadjuvant therapy is defined as a treatment 
administered prior to the main (usually surgical) treatment 
for a particular neoplasm. It is used not only to eliminate 
circulating tumor cells but also to reduce the size of the 
tumor, thereby facilitating surgery and perhaps increasing 
the chance of organ preservation. Since imatinib results 
in significant tumor shrinkage in at least 50% of treated 
patients,3,4 its use as a neoadjuvant treatment is logical.
CASE REPORT
A 32-year-old man, otherwise fit and healthy, underwent 
medical evaluation for hematochezia lasting a month. A 
complete proctological examination revealed a bulge in the 
anterior rectal wall, approximately 5 cm above the dentate 
line. The rectal mucosa was normal upon digital examination 
and rigid proctoscopy, which confirmed the rectal bulge. 
A complete colonoscopy was unremarkable except for the 
findings described in the proctological examination. Routine 
laboratory tests and tumor markers were normal (CEA = 
0.6; CA 19-9 = 8.1). An MRI of the abdomen and pelvis 
demonstrated a well-demarcated solid pelvic mass (9.3 cm 
x 8.3 cm x 6.5 cm; 257 cc) (Figures 1 and 2) compressing 
the bladder, prostate and rectum. While the tumor appeared 
to have infiltrated the muscular wall of the rectum, no other 
unusual findings were observed. A chest X-ray was normal, 
but a transperineal CT-guided biopsy was positive for a 
GIST. After a multidisciplinary discussion regarding the 
known risk of incomplete surgical resection, the patient was 
treated with 400 mg/d imatinib mesylate for 6 weeks in order 
to reduce the size of the tumor and increase the likelihood 
of curative surgery. An MRI after 6 weeks of imatinib 
mesylate treatment demonstrated a marked reduction in 
tumor size (6.3 cm x 5.6 cm x 4.7 cm; 86 cc) (Figure 1 and 
2). The patient was maintained on imatinib mesylate for 
another 4 weeks, after which a second MRI revealed no 
further decrease in the size of the lesion, and the patient was 
referred for surgery. 
The patient underwent laparoscopic-assisted resection 
of the rectal GIST with partial removal of the anterior rectal 
wall, which was reconstructed using a manual suture. Frozen 
sections of the margins were negative. Since the suture 
was located 3 cm above the dentate line, a temporary loop 
ileostomy was made. Pathological examination confirmed 
a GIST (CD117 positive, CD34 positive) that was 6.5 cm x 
5.0 cm x 2.0 cm in size with a low mitotic rate. The patient’s 
recovery was uneventful, and he was discharged on post-
operative day 4. He was advised to continue with imatinib 
mesylate treatment for another 9 months, completing one 
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year of treatment. The loop ileostomy was closed 12 weeks 
after the tumor was removed with no complications.
DISCUSSION
GISTs can be unresectable or, as in our report, resectable 
tumors requiring extensive organ disruption in order to 
achieve complete resection. Therefore, the use of imatinib 
prior to surgical resectioning to reduce the tumor size is 
an attractive approach. Since 2003, several case reports 
regarding the use of neoadjuvant treatment for GIST have 
been published, and one phase II trial has been completed. 
The usual therapeutic regimen involves a course of imatinib, 
commonly administered for 3 to 12 months, with frequent 
imaging studies and a re-evaluation of the best time for 
surgery. The decision regarding the best time to operate, 
which should take into account both resectability and 
the maximum therapeutic effect remains controversial, 
particularly since tumor progression can occur rapidly even 
after a substantial tumor shrinkage. Progression of the tumor 
establishes a clinical dilemma: if radical salvage surgery 
is possible, it remains a reasonable therapeutic option as 
opposed to performing salvage systemic therapy, which 
would likely have little chance of achieving a substantial 
reduction in tumor size. Unfortunately, the long-term results 
for surgery performed on refractory tumors are typically 
worse. The resectioning of progressive disease appears to 
benefit only those patients with focal progression and has 
little to offer to those who experience generalized disease 
progression while receiving imatinib.5-9
The preliminary data suggesting the benefits of 
neoadjuvant treatment with imatinib were obtained in a 
phase II trial (RTGO 0132) carried out by the Radiation 
Therapy Oncology Group (RTOG).12 This study included 
patients with biopsy-proven GIST that was classified as 
either potentially resectable primary disease (≥5 cm) or 
potentially resectable locally recurrent or metastatic disease 
(≥ 2 cm). Between February and June of 2006, 63 patients 
from 18 institutions were treated with imatinib (600 mg/
day) for 8 to 12 weeks prior to surgical resection and two 
additional years of imatinib treatment. Among the 52 
patients analyzed, 30 patients had locally advanced disease, 
and 22 patients had recurrent/metastatic disease. Surgery 
was performed in 45 of the 52 cases, and one patient died 
due to an infectious complication. A response to pre-
operatory imatinib (RECIST) was observed in 2 patients 
(7%) with locally advanced disease and 25 patients (83%) 
with stable disease. None of these tumors progressed during 
treatment. Within 2 years of the termination of treatment, 
the progression free survival and overall survival for those 
patients who presented with locally advanced disease were 
82% and 93%, respectively. This trial demonstrated that 
pre-operative treatment with imatinib is safe with minimal 
drug-related toxicity and surgical morbidity. The PFS 
and OS are favorable for this group with high-risk GIST. 
Despite these promising results, this strategy is currently 
not recommended for use outside of a clinical trial. The only 
reasonable exception would be the use of imatinib mesylate 
by an experienced multidisciplinary team when an objective 
response could result in organ preservation.
Figure1 - Pre- and post-treatment MRI (sagittal) illustrating the reduction 
in tumor size
Figure 2 - Pre- and post-treatment MRI illustrating the reduction in tumor 
size
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